A landmark ruling over the use of puberty-blocking drugs for children with gender dysphoria will not be challenged at the Supreme Court.
In late 2020, the High Court ruled it was “highly unlikely” that a child aged 13 or under would be able to consent to hormone-blocking treatment, and that it was “very doubtful” that a child of 14 or 15 would understand the long-term consequences.
